Therapeutic Trial with N-Acetylcysteine in Amyotrophic Lateral Sclerosis
The first promising results of the effect of N-acetylcysteine in amyotrophic lateral sclerosis (ALS), reported by den Hartog Jager[l], encouraged us to start a parallel open study with this agent. Since the beginning of 1984, 15 patients have entered this trial which for the first patients has now reached 12 months of duration. We report our experience with N-acetylcysteine in 11 patients who could be followed for a sufficient period to draw preliminary conclusions.
KeywordsAmyotrophic Lateral Sclerosis Vital Capacity Duchenne Dystrophy Amyotrophic Lateral Sclerosis Patient Impaired Pulmonary Function
Unable to display preview. Download preview PDF.
- 1.W. A. den Hartog Jager, Experimental amyotrophic lateral sclerosis in the Guinea-pig. Cause and prevention. An animal model, in: “Trends in ALS-Research”, A. Struppler and G. Rüther, eds., pp. 125 - 134, Arwin-Verlag, Munich (1984).Google Scholar
- 2.Medical Research Council, “Aids to the Investigation of Peripheral Nerve Injuries”, Her Majesty’s Stationary Office, London (1976).Google Scholar
- 4.M. H. Brooke, G. M. Fenichel, R. C. Griggs, J. R. Mendell, R. Moxley, P. L. Miller, M. A. Province, and C. Group, Clinical investigation in Duchenne dystrophy. II. Determination of the “power” of therapeutic trials based on the natural history, Muscle Nerve, 6: 91–103 (1983).Google Scholar
- 5.J. Cohen, “Statistical Power Analysis for Behavioral Sciences”, Academic Press, New York (1977).Google Scholar